ABIVAX Société Anonyme Past Earnings Performance
Past criteria checks 0/6
ABIVAX Société Anonyme's earnings have been declining at an average annual rate of -30.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 6.4% per year.
Key information
-30.3%
Earnings growth rate
-12.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 6.4% |
| Return on equity | -113.7% |
| Net Margin | -457,550.0% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ABIVAX Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -92 | 12 | 66 |
| 31 Mar 23 | 0 | -76 | 10 | 57 |
| 31 Dec 22 | 0 | -61 | 7 | 48 |
| 30 Sep 22 | 2 | -50 | 6 | 63 |
| 30 Jun 22 | 2 | -47 | 4 | 63 |
| 31 Mar 22 | 1 | -45 | 5 | 55 |
| 31 Dec 21 | 0 | -42 | 6 | 48 |
| 30 Sep 21 | 0 | -41 | 6 | 24 |
| 30 Jun 21 | 0 | -39 | 6 | 0 |
| 31 Mar 21 | 0 | -38 | 6 | 0 |
| 31 Dec 20 | 0 | -38 | 6 | 0 |
| 30 Sep 20 | 0 | -35 | 5 | 0 |
| 30 Jun 20 | 0 | -32 | 5 | 0 |
| 31 Mar 20 | 0 | -31 | 5 | 0 |
| 31 Dec 19 | 0 | -31 | 5 | 0 |
| 30 Sep 19 | 0 | -27 | 5 | 0 |
| 30 Jun 19 | 0 | -23 | 5 | 0 |
| 31 Mar 19 | 1 | -19 | 5 | 0 |
| 31 Dec 18 | 1 | -16 | 4 | 0 |
| 30 Sep 18 | 1 | -14 | 4 | 0 |
| 30 Jun 18 | 1 | -13 | 4 | 0 |
| 31 Mar 18 | 1 | -12 | 4 | 0 |
| 31 Dec 17 | 0 | -11 | 4 | 0 |
| 30 Sep 17 | 0 | -11 | 4 | 0 |
| 30 Jun 17 | 0 | -12 | 4 | 0 |
| 31 Mar 17 | 0 | -13 | 4 | 0 |
| 31 Dec 16 | 0 | -14 | 4 | 0 |
| 30 Sep 16 | 0 | -16 | 4 | 0 |
| 30 Jun 16 | 0 | -17 | 4 | 0 |
| 31 Mar 16 | 0 | -17 | 4 | 0 |
| 31 Dec 15 | 0 | -16 | 3 | 0 |
| 30 Sep 15 | 0 | -14 | 3 | 0 |
| 30 Jun 15 | 0 | -12 | 3 | 0 |
| 31 Mar 15 | 0 | -8 | 2 | 0 |
| 31 Dec 14 | 0 | -5 | 2 | 0 |
Quality Earnings: ABVXp is currently unprofitable.
Growing Profit Margin: ABVXp is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABVXp is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Accelerating Growth: Unable to compare ABVXp's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABVXp is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: ABVXp has a negative Return on Equity (-113.69%), as it is currently unprofitable.